Indoco Remedies (INDOCO) Hisse Özeti
Indoco Remedies Limited, Hindistan'da ve uluslararası alanda formülasyonlar ve aktif farmasötik bileşenler üretmekte, pazarlamakta ve satmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
INDOCO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Indoco Remedies Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | ₹244.02 |
| 52 Haftanın En Yüksek Seviyesi | ₹349.80 |
| 52 Haftanın En Düşük Seviyesi | ₹162.19 |
| Beta | 0.57 |
| 1 Aylık Değişim | 17.74% |
| 3 Aylık Değişim | 30.30% |
| 1 Yıllık Değişim | -27.98% |
| 3 Yıllık Değişim | -25.28% |
| 5 Yıllık Değişim | -46.63% |
| Halka arzdan bu yana değişim | 364.21% |
Son Haberler & Güncellemeler
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.Recent updates
INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook
Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.INDOCO: Ophthalmic Business Transfer Will Shape Bullish Outlook
Analysts have kept the fair value for Indoco Remedies steady at ₹250, as small adjustments to revenue growth, profit margin, and future P/E assumptions offset each other rather than pointing to a clear shift in the stock's valuation story. What's in the News The Malta Medicines Authority inspected Indoco Remedies' solid oral dosage facility at Baddi (Unit I) from January 29, 2026 to February 3, 2026 and granted EU GMP certification confirming compliance with Good Manufacturing Practice requirements under the EC Directive.The Indoco Remedies Limited (NSE:INDOCO) Annual Results Are Out And Analysts Have Published New Forecasts
Investors in Indoco Remedies Limited ( NSE:INDOCO ) had a good week, as its shares rose 8.8% to close at ₹228 following...INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook
Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...Earnings Update: Here's Why Analysts Just Lifted Their Indoco Remedies Limited (NSE:INDOCO) Price Target To ₹259
Indoco Remedies Limited ( NSE:INDOCO ) last week reported its latest quarterly results, which makes it a good time for...Indoco Remedies Limited (NSE:INDOCO) Soars 27% But It's A Story Of Risk Vs Reward
The Indoco Remedies Limited ( NSE:INDOCO ) share price has done very well over the last month, posting an excellent...Revenues Working Against Indoco Remedies Limited's (NSE:INDOCO) Share Price Following 25% Dive
Indoco Remedies Limited ( NSE:INDOCO ) shares have had a horrible month, losing 25% after a relatively good period...
Plant Remediation And Clarity Pharma Partnership Will Support Future Market Expansion
Resolving manufacturing plant issues is critical for increasing U.S. market supply, boosting revenue, and minimizing compliance risks.₹294: That's What Analysts Think Indoco Remedies Limited (NSE:INDOCO) Is Worth After Its Latest Results
There's been a notable change in appetite for Indoco Remedies Limited ( NSE:INDOCO ) shares in the week since its...Indoco Remedies Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a mediocre week for Indoco Remedies Limited ( NSE:INDOCO ) shareholders, with the stock dropping 11% to ₹304...Earnings Troubles May Signal Larger Issues for Indoco Remedies (NSE:INDOCO) Shareholders
A lackluster earnings announcement from Indoco Remedies Limited ( NSE:INDOCO ) last week didn't sink the stock price...Earnings Miss: Indoco Remedies Limited Missed EPS By 56% And Analysts Are Revising Their Forecasts
It's shaping up to be a tough period for Indoco Remedies Limited ( NSE:INDOCO ), which a week ago released some...Does Indoco Remedies (NSE:INDOCO) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Indoco Remedies Limited's (NSE:INDOCO) CEO For Now
Performance at Indoco Remedies Limited ( NSE:INDOCO ) has been reasonably good and CEO Sundeep Bambolkar has done a...Here's Why Indoco Remedies (NSE:INDOCO) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Indoco Remedies (NSE:INDOCO) Has Announced That It Will Be Increasing Its Dividend To ₹1.50
Indoco Remedies Limited ( NSE:INDOCO ) has announced that it will be increasing its dividend on the 23rd of October to...Does Indoco Remedies (NSE:INDOCO) Deserve A Spot On Your Watchlist?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...Indoco Remedies (NSE:INDOCO) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Hissedar Getirileri
| INDOCO | IN Pharmaceuticals | IN Pazar | |
|---|---|---|---|
| 7D | 5.4% | 1.3% | -0.06% |
| 1Y | -28.0% | 12.0% | -2.1% |
Getiri vs. Endüstri: INDOCO geçen yıl % 12 oranında getiri sağlayan Indian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: INDOCO geçen yıl % -2.1 oranında getiri sağlayan Indian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| INDOCO volatility | |
|---|---|
| INDOCO Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.5% |
| 10% least volatile stocks in IN Market | 4.1% |
İstikrarlı Hisse Senedi Fiyatı: INDOCO hisse senedi fiyatı, son 3 ayda Indian piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: INDOCO 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala Indian hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1945 | 6,000 | Sundeep Bambolkar | www.indoco.com |
Indoco Remedies Limited, Hindistan'da ve uluslararası alanda formülasyonlar ve aktif farmasötik bileşenler üretmekte, pazarlamakta ve satmaktadır. Stomatolojik, gastrointestinal, solunum, anti-enfektifler, vitaminler/mineraller/besinler, oftalmolojik/ontolojik, dermatoloji, ürolojik, anti-diyabetik, jinekolojik, yaşam tarzı yönetimi, ağrı/analjezik ve kardiyak ürünler sunmaktadır. Şirket ayrıca analjezik tabletler ve topikal preparatlar; anti-hipertansif; protein takviyeleri; multivitamin tabletleri ve şurupları; antibiyotik tabletleri, şurupları ve enjektablları; oral rehidrasyon tozları; antiasitler ve antihistaminiklerin yanı sıra hemoroidal kremler ve kalsiyum preparatlarından oluşan markalı jenerik ürünler de sunmaktadır.
Indoco Remedies Limited Temel Bilgiler Özeti
| INDOCO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | ₹21.85b |
| Kazançlar(TTM) | -₹951.50m |
| Gelir(TTM) | ₹18.45b |
INDOCO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| INDOCO gelir tablosu (TTM) | |
|---|---|
| Gelir | ₹18.45b |
| Gelir Maliyeti | ₹5.42b |
| Brüt Kâr | ₹13.04b |
| Diğer Giderler | ₹13.99b |
| Kazançlar | -₹951.50m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -10.31 |
| Brüt Marj | 70.64% |
| Net Kâr Marjı | -5.16% |
| Borç/Özkaynak Oranı | 111.1% |
INDOCO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/02 16:00 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Indoco Remedies Limited 11 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| Srivathsan Ramachandran | Avendus Spark |